Michael Rivard News
Most Popular Michael Rivard Story
VaxDesign offers an alternative to animal studies
Time magazine profiles the work of VaxDesign, a five-year-old biotech company that has developed simulated human immune systems, mixing blood cells and faux tissue into a special construct that can... Read more...
Latest Headlines
- April 3, 2008
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
